NPs and PAs
Upon completion of this activity, participants should be able to:
Identify signs and symptoms of IBD in both pediatric and adult patients to allow for early diagnosis and treatment
Summarize the impact of biologic therapies and small-molecule inhibitors on treatment goals for IBD
Outline expanded therapeutic indications and new and emerging treatment options for pediatric and adult IBD
Implement recommended strategies for the long-term management of patients with IBD
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Dermot McGovern, MD, PhD, FRCP, FACG
Professor of Medicine
Translational Research in the Inflammatory Bowel and Immunobiology Research Institute
Cedars-Sinai Medical Center
Los Angeles, California
Dermot McGovern, MD, PhD: consultant/advisor/speaker: Gilead, Pfizer, Prometheus Biosciences, Prometheus Laboratories, Takeda; stock options: Prometheus Biosciences.
Susan M. Tiso, DNP, APRN, FNP-BC, FAANP
Clinical Professor, Retired
Sue & Bill Gross School of Nursing
Family Nurse Practicioner, Retired
University of California, Irvine
Susan Tiso, DNP, APRN, FNP-BC, has no relevant financial relationships to disclose.
None of the members of the Planning Committee or PCE staff have any relevant financial relationships to disclose, except Dermot McGovern, MD, PhD as noted above.
Participants wishing to earn CE/CME credit must:
The estimated time to complete this activity is 1.00 hour.
Release date: September 30, 2022
Expiration date: September 29, 2023
This program has been made available online.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
Joint Accreditation Statement
In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
NP course advisor: Susan Tiso, DNP, FNP-BC, University of California, Irvine, Irvine, California
Nursing contact hours: 1.00, which includes 1.00 hours of pharmacology credit
AAPA Credit Designation
Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid until September 29, 2023. PAs should only claim credit commensurate with the extent of their participation.
PA course advisor: Tracey M. Piparo, PA-C, RWJ Barnabas Health, New Brunswick, New Jersey
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credits for learning and change.